Join us for The Singulex BioRemarkable Dinner following the Thursday activities of IDWeek™ 2018!

Featuring: Niaz Banaei, MD, Glen Hansen, PhD, Nira Pollock, MD, PhD, D (ABMM), Stephen Young, PhD

You are invited to discuss a standalone solution for diagnosing Clostridium difficile infection (CDI). This invitation-only dinner event is your opportunity to meet with peers and industry leaders to discuss the latest research data for a novel diagnostic method for CDI. Using Singulex’s proprietary Single Molecule Counting technology, this new diagnostic is designed to identify true CDI with:

Higher specificity than NAAT
Higher sensitivity than currently available immunoassays
A rapid, single, standalone test

Together with our distinguished speakers, we will discuss the possibility of eliminating current multi-step algorithms with this single-test solution, the Singulex Clarity® C. diff toxin A/B assay (currently in development; not yet available for commercial sale). This test is designed to conform with the new CDI guidelines and t has the potential to eliminate the cascade of complications and cost implications that result from the diagnostic uncertainty of traditional methods.

Our speakers include:

Niaz Banaei, MD

Associate Professor of Pathology and of Medicine (Infectious Diseases) at the Stanford University Medical Center, and Medical Director for the Stanford Health Care Clinical Microbiology Laboratory

Glen Hansen, PhD

Associate professor at the Department of Pathology & Laboratory Medicine and Department of Medicine (Infectious Diseases) at University of Minnesota, and Medical Director for the Clinical Microbiology and Molecular Diagnostics Laboratory at Hennepin County Medical Center HCMC

Nira Pollock, MD, PhD, D (ABMM)

Associate Medical Director at the Infectious Diseases Diagnostic Laboratory at Boston Children's Hospital and Assistant Professor of Medicine and Pathology at Harvard Medical School

Stephen Young, PhD

Professor Emeritus of Pathology at University of New Mexico, and Director of Research and Clinical Trials at TriCore Reference Laboratories

Singulex adheres to all applicable state and federal aggregate spend reporting requirements.

Higher specificity than NAAT

Higher sensitivity than currently available immunoassays

A rapid, single, standalone test

Registrations are closed

Simplifying the Complexities of CDI Diagnostics